Shenzhen, China, 9 September, 2025–MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of data in just 24 hours while offering a smaller footprint, flexible run configurations, and end-to-end automation. Internally dubbed a “data mining machine,” the T7+ redefines high-throughput sequencing by combining daily output with ease of use and multi-omics versatility.

A New Era in High-Throughput Sequencing

The T7+ integrates MGI’s proprietary DNBSEQ™ technology with next-generation fluidics, optics, and bioinformatics, creating a platform that is faster, smarter, and more versatile than ever before. The compact system supports 1–4 flow cells per run, adapts to projects of any scale, and integrates every step—from DNB preparation to bioinformatics analysis—into a fully automated workflow.

Key technical highlights include:

· Throughput: More than 14 Tb/day (vs. 7 Tb/day on T7)

· Annual Capacity: Up to 35,000 whole-genome sequencing (WGS)

· Accuracy: >90% Q40 quality scores, validated in beta testing by leading labs

· Speed: PE150 reads in under 24 hours

· Flexibility: Configurable for mid- or large-scale studies

· Size Efficiency: 1 m²

· 7-in-1 Integration: Hardware + software architecture eliminates manual preparation steps

· Scanning Time: 50% reduced by the TDI(Time-Delay Integration) camera.

· One-Stop Workflow: Built-in automation from DNB preparation to bioinformatics

· Reduced energy consumption: Over 90% of transport links and certain reagents require no cold chain.

With these capabilities, the T7+ enables researchers to sequence 144 human genomes in a single day, accelerating breakthroughs in cancer genomics, rare disease research, and precision medicine.

From T7 to T7+: Continuing the T Series Legacy

The DNBSEQ-T7, launched in 2018, was a breakthrough in the T Series, setting a new benchmark for high-throughput sequencing by delivering up to 7 terabases (Tb) of data in 24 hours. With over 400 units installed at more than 200 leading institutions worldwide, such as national initiatives, including Thailand’s Genomics Thailand Initiative and Brazil’s largest genomic sequencing project. This milestone redefined sequencing speed and accessibility, cementing the T Series as a cornerstone of genomic innovation.

As sequencing becomes increasingly  affordable, researchers are demanding  instruments that deliver higher throughput, faster results, and uncompromising accuracy and quality. That’s why MGI developed the T7+, an advanced continuation of the T7 designed to deliver greater speed, scalability, high flexibility, and performance to meet the evolving demands of clinical research, population genomics, and large-scale sequencing projects.

T7 was a breakthrough in specs, while the T7+ breaks new ground in user experience.

Redefining High-Throughput Sequencing

T7+ solves the universal trade-offs researchers face—speed versus capacity, usability versus cost. By integrating 7-in-1 hardware, smartphone-like software, and modular-designed consumables, the T7+ makes sequencing as intuitive as using a smartphone. Its ability to support multi-omics applications—spatial omics, single-cell, proteomics, methylation—in one run enables concurrent data streams for large cohorts.

“The T7+ is more than just a sequencer—it is a bridge between scientific discovery and real-world health outcomes,” added Duncan Yu, President of MGI Tech. “With higher throughput, improved accuracy, and a smaller footprint, the T7+ empowers scientists to ask bigger questions and deliver insights faster. Every genome sequenced has the potential to accelerate rare disease diagnosis, guide precision oncology, and inform public health at scale.”

Early adopters of the T7+ are already deploying it in population-scale studies, where its short-read power, combined with cyclone long-read data, enhances structural variant detection and rare disease analysis. Others are pairing the T7+ with long-read platforms for single-cell studies, opening new opportunities in understanding genetic diversity and cellular complexity.

T7+ is now open to order. International shipments begin in late 2025.

About MGI:

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.